Drug Profile


Alternative Names: BB 3644

Latest Information Update: 18 Feb 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator British Biotech
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Metalloprotease inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 06 Aug 2003 Discontinued - Preclinical for Inflammatory bowel disease in United Kingdom (PO)
  • 06 Aug 2003 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (PO)
  • 11 Oct 2001 Rights to solimastat have been returned to British Biotech by Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top